valu usd unless otherwis note
move under-perform rate guid
behind us still struggl growth
view move sector perform target follow guidanc
updat sell-off updat remov
ebitda debat concern risk multi-year street forecast
like limit downsid confid out-year
growth remain low anticip fremanezumab delay challeng bull
case still link multi-year de-lev take time come
cut forecast ebitda achiev out-year
growth less clear new ebitda billion
billion billion see continu revenu degrad weigh
teva abil grow link billion cost cut
necessari effect address near-term patent cliff
solv teva growth problem still think bull case over-
estim medium-term growth given deep cost cut multi-year
period lack busi develop support said outlook
feel conserv cost save mechan provid
 support next year bottom line think share
larg rang bound go forward fewer upside/downsid catalyst
dictat bull/bear path weigh-in three import point
fremanezumab delay view like given celltrion
warn letter singl sourc api disclosur stock
surpris understand frustrat given import
competit time fact teva point pdufa
jun austedo million revenu still ramp
two primari growth driver delay impact cost
would presum push think justifi prolong
delay could cut peak
convinc teva grow import point
ebitda step cost cut support
sure grow question go
away amend debt coven impli growth per model
reflect billion debt reduct annual teva trip leverag
ceil much room near term coven set
gener copaxon updat
cap outlook room lot
teva bull case appli better upsid thesi
wait de-lev leverag net debt
put trough price-to-earnings ep number make
sens impli upsid analysi versu
teva ambiti come meaning less
leverag growth stronger pipelin less risk current ev/
ebitda also hard justifi teva premium
price prior trade day market close estimate unless otherwis note
teva hold global lead diversifi gener footprint
shown immun sector headwind given
size expect pressur continu
specialti brand busi potenti provid
off-set road focu around new gener
competitor target largest product copaxon
given heighten leverag financi flexibl diversifi
exist headwind remain limit primari driver
thesi
acquisit gener busi add gener
ebitda pipelin effect doubl
sector peak
brand pipelin progress cgrp next
key opportun believ growth
blunt gener entri copaxon
exist leverag billion debt like
remain overhang financi risk particularli
pressur ebitda base cash flow remain
think busi develop limit non-
exist teva de-lev toward may
happen model
potenti catalyst focu fremanezumab pdufa
jun well celltrion api supplier warn letter
updat addit gener entrant copaxon
risk credit rating/coven complianc
risk view primari risk stock
rate could potenti miss delay fremanezumab
launch due and/or slower expect uptak
lower expect austedo sale ramp
higher expect top-lin impact base busi
aggress cost cut continu price pressur
multipl gener copaxon approv
weak cash flow gener jeopard debt pay
bloomberg capit market estim upside/downside/target
price target impli price-to-earnings ep
ev/ebitda billion ebitda
addit gener entri copaxon earli
million new gener launch revenu annual
doubl digit base eros per year
capit deploy toward debt reduct billion
per year assum
next major brand
upsid scenario base impli ev/ebitda
multipl ebitda current
forecast also impli price-to-earnings appli ep
success ramp earlier approval/ramp cgrp
de-lev end potenti pick-up
downsid scenario base assum
ev/ebitda valuat ebitda current
forecast also impli price-to-earnings ep
copaxon impact gener entri
expect sever competitor enter
free cash flow shortfal lead reduc debt reduct
exhibit teva segment build
teva segment busi us gener teva us gener august close eu gener teva row gener teva eu gener august close row gener gener us gener teva eu gener teva row gener teva us gener eu gener row gener eu row gener gross gener analysi us gener gm eu gener gm row gener eu row over-the-counter gross ebit gross ebit exhibit teva segment build cont
teva segment busi specialti specialti specialti specialti gross specialti specialti analysi specialti gross specialti ebit gross specialti ebit distributionnet close fy guidanc guidanceseg gross gross includ overal line assumptionadjust ebit total exhibit teva
teva incom state reflect anda flow-through rest world includ total revenu guid billioncost gross profit guid billion slightli lower gener incom guid billionoth incom guid financ expens tax debt paydown epsless provis incom guid tax ratenet incom add-back prefer ep add-back adjust share countadjust net ep pro-forma guid share account share convers dilut neutral ep fulli dilut share guid million share dividend per ebitda guid billion ebitda guid overal gm expens guid tax rateadjust net incom analysi net pharmaceuticals/specialti
price target base equal price-to-earnings ev/ebitda reflect teva moder
lower tax rate current leverag price target base multipl
respect reflect uniqu fundament risk current environ ii
uncertainti around addit gener copaxon launch iii brand pipelin
without risk iv leverag risk heighten level multipl appli
forecast roughli line peer level compani histor ebitda
multipl potenti valuat re-rat exist growth begin inflect leverag
move lower view could take sever year price target support sector
risk rate price target
follow could lead teva realiz downsid price target rate
delay fremanezumab launch due and/or slower expect uptak lower
expect austedo sale ramp higher expect top-lin impact
base busi aggress cost cut continu price pressur multipl gener
copaxon launch weak cash flow gener jeopard debt pay
coven complianc
teva global pharmaceut compani headquart israel engag
manufactur pharmaceut over-the-counter product revenu come
unit state remaind broad global footprint compani grown
rapidli year combin aggress acquir well-known compani
ivax barr lab ratiopharm cephalon among mani other follow year
rapid growth teva look address sever growth challeng broad cost-
restructur program life-cycle manag strategi copaxon
